Minerva Neurosciences

NERV · Nasdaq · United States

Share price · NERV

$2.18-2.36 (-51.98%) 3M

close as of 2026-11-18 · 24h delayed · vol 278K (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NERV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Oct 2026-13.0%

    Nothing announced by NERV that day or the session before.

  2. 14 Aug 2026+16.8%
  3. 29 Jun 2026+24.3%

    Nothing announced by NERV that day or the session before.

  4. 23 Mar 2026-13.1%

    Nothing announced by NERV that day or the session before.

  5. 9 Mar 2026+33.1%
  6. 5 Mar 2026-13.0%
  7. 10 Feb 2026+11.7%

    Nothing announced by NERV that day or the session before.

  8. 9 Feb 2026+17.7%

    Nothing announced by NERV that day or the session before.

  9. 2 Feb 2026+15.3%

    Nothing announced by NERV that day or the session before.

Share of unusual movement by asset

For each asset, the share of NERV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Roluperidone
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—95%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Sigma-2 receptor complex · Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule
Schizophrenia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
RoluperidonePhase 3Negative Symptoms of Schizophrenia
Est. primary completion 2027-12 · NCT07565428 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 February 2024Complete response letterRoluperidoneFDA Complete Response Letter on the roluperidone NDA
US, FDA · FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.2M$20M+ $57M short-term inv.—-$8.2M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$7.2M$25M+ $51M short-term inv.—-$13M operating cash flowreport ↗
2026-Q1—$5.3M$33M+ $45M short-term inv.$125M-$5.4M operating cash flowreport ↗
2025-Q3—$0.9M$12M$2.7M-$2.9M operating cash flowreport ↗
2025-Q2—$1.3M$15M$3.3M-$2.0M operating cash flowreport ↗
2025-Q1—$1.4M$17M$3.8M-$4.1M operating cash flowreport ↗
2024-Q3—$1.9M$27M—-$4.3M operating cash flowreport ↗
2024-Q2—$3.9M$31M$8.2M-$3.9M operating cash flowreport ↗
2024-Q1—$4.2M$35M$8.6M-$6.1M operating cash flowreport ↗
2023-Q3—$3.4M$47M$7.8M-$4.8M operating cash flowreport ↗
2023-Q2—$1.9M$52M$6.2M-$3.9M operating cash flowreport ↗
2023-Q1—$2.6M$36M$7.0M-$0.1M operating cash flowreport ↗
2022-Q3—$2.4M$40M$6.9M-$9.5M operating cash flowreport ↗
2022-Q2—$4.1M$50M$8.7M-$5.2M operating cash flowreport ↗
2022-Q1—$5.0M$55M$9.8M-$5.8M operating cash flowreport ↗
2021-Q3—$4.5M$66M$9.2M-$8.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$5.8M$82M$73M-$14M operating cash flowreport ↗

For fiscal 2025, Minerva Neurosciences reported no revenue, as it was not disclosed (prior year: $0M). R&D spend was $5.76M, down 51.6% YoY, and cash and equivalents stood at $82.3M. The company recorded a net loss of $293.42M for the year.

Minerva plans to initiate a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027, following general alignment with the FDA on the trial design. In October 2025, it received $80.0M in gross proceeds from a private placement, with potential additional proceeds from warrant exercises, and management anticipates sufficient funds to complete the Phase 3 trial and NDA resubmission.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$12M$21M—-$20M operating cash flowreport ↗
2023-FY$0$13M$41M$7.5M-$15M operating cash flowreport ↗
2022-FY$0$15M$36M$8.0M-$25M operating cash flowreport ↗
2021-FY$0$32M$61M$12M-$25M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Kaul Inderjit · directorAward / grant (derivative)2,328——Form 4
2026-08-03Kaul Inderjit · directorAward / grant (derivative)12,147——Form 4
2026-06-03HASLER HANS PETER · directorAward / grant (derivative)50,000——Form 4
2026-06-03VAN HEEK G JAN · directorAward / grant (derivative)50,000——Form 4
2026-06-03Kaul Inderjit · directorAward / grant (derivative)50,000——Form 4
2026-06-03Kupfer David · directorAward / grant (derivative)50,000——Form 4
2026-06-03Laghrissi-Thode Fouzia · directorAward / grant (derivative)50,000——Form 4
2026-06-03Luthringer Remy · director, CEOAward / grant (derivative)1,690,700——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 44 reporting institutions held 38.3M shares ($230.7M, 76.8% of shares outstanding).

#InstitutionSharesValue
1FEDERATED HERMES, INC.5,113,224$30.8M
2Vivo Capital, LLC4,322,747$26.0M
3JANUS HENDERSON GROUP PLC4,294,259$25.9M
4Balyasny Asset Management L.P.4,258,600$25.7M
5Logos Global Management LP3,215,000$19.4M
6FARALLON CAPITAL MANAGEMENT LLC2,365,000$14.2M
7Foresite Capital Management VI LLC1,986,600$12.0M
8VANGUARD CAPITAL MANAGEMENT LLC1,845,831$11.1M
9Ally Bridge Group (NY) LLC1,655,500$10.0M
10Spruce Street Capital LP1,655,500$10.0M
11Trails Edge Capital Partners, LP1,419,000$8.5M
12ADAGE CAPITAL PARTNERS GP, L.L.C.1,419,000$8.5M
13DV Trading LLC889,254$5.4M
14ACUTA CAPITAL PARTNERS, LLC709,500$4.3M
15MILLENNIUM MANAGEMENT LLC708,291$4.3M